ALGN vs HALO: fair value comparison
Align Technology, Inc. and Halozyme Therapeutics, Inc. · Updated 2026-09-07
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, ALGN currently sits closer to the top of our discount ranking. HALO carries the stronger quality grade.
| ALGN | HALO | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $158.63 | $82.27 |
| 12-month range | $137.88–$189.02 | $63.96–$82.27 |
| Sector rank | #10 of 113 Healthcare | #14 of 113 Healthcare |
| Quality grade | B | A |
| Momentum grade | — | A |
| Leverage | Low | High |
| Margin trend | Stable | Expanding |
| Revenue growth | Modest | High |
| RSI zone | Neutral | Overbought |
| 50/200-day trend | Mixed | Mixed |
| DCF cross-check | Overvalued | Fairly Valued |
| 52-week position | The lower-middle quarter | The top quarter |
Full single-stock breakdowns: ALGN fair value analysis · HALO fair value analysis